Multiple sclerosis (MS) is the commonest non‐traumatic disabling disease to affect young
adults. The incidence of MS is increasing worldwide, together with the socioeconomic …

The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …

Multiple Sclerosis (MS) is a major cause of neurological disability, which increases
predominantly during disease progression as a result of cortical and grey matter structures …

Vitamin D and its main active metabolite 1, 25-dihydroxyvitamin D serve a crucial role in
maintenance of a healthy calcium metabolism, yet have additional roles in immune and …

Two different treatment paradigms are most often used in multiple sclerosis (MS). An
escalation or induction approach is considered when treating a patient early in the disease …

Current therapeutic landscape in multiple sclerosis: an evol... : Current Opinion in
Neurology Current therapeutic landscape in multiple sclerosis: an evolving treatment …

Dimethyl fumarate (Tecfidera®) is approved for the treatment of relapsing forms of multiple
sclerosis (MS). Based on evidence from the clinical trial and real-world settings, dimethyl …